文献速递心境障碍

锂盐作为双相障碍的疾病修饰药物

Lithium as a disease-modifying drug for bipolar disorder.
PubMed 文献 · Lancet Psychiatry · 2025-06-09

本文为个人观点文章,提出双相障碍是慢性、可能进展性疾病,每次心境发作可加重病情。作者论证锂盐在DNA、细胞、脑结构与功能等多层面独特影响双相障碍相关机制,试验与队列证据显示其疗效可能优于其他药物且长期结局更好,主张将锂盐视为疾病修饰药物以促进早期使用。

要点

  • 锂盐是双相障碍经典一线治疗,但临床使用随时间下降,尤其在北美。
  • 作者主张将锂盐视为疾病修饰药物,以促进医生尤其早期病程中的使用。
  • 临床试验与队列研究证据显示锂盐疗效可能优于其他双相障碍药物,长期结局优于非锂方案。

核心结论

  • 作者认为锂盐在双相障碍中起疾病修饰药物作用,将这一概念化有助于提高临床使用,尤其在疾病早期。

研究设计与样本

  • 本文为Personal View(个人观点)文章,未报告系统检索方法或样本量;论证基于对双相障碍病理生理与锂盐作用机制的综述性讨论。

主要发现

  • 双相障碍日益被视为慢性、可能进展性疾病,每次心境发作可加重和加速病情。
  • 双相障碍的许多相关机制及替代标志物受锂盐治疗独特影响,涉及DNA、细胞水平到脑结构与功能及其他身体系统。
  • 临床试验和队列研究证据显示锂盐有效,且可能优于其他治疗双相障碍的药物;长期结局锂盐优于非锂方案。

临床怎么用

  • 作者建议将锂盐概念化为疾病修饰药物,以帮助提高医生的临床使用,尤其在疾病早期以更好服务患者。

局限性

  • 双相障碍的病理生理仍不明确;本文为个人观点文章,论证基于对现有机制与证据的解读,未报告系统检索或定量合并。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lithium is a classic, primary treatment for bipolar disorder that has paradoxically been used less over time, especially in North America, which goes against the accumulating evidence for its efficacy. Bipolar disorder is increasingly conceptualised as a chronic, potentially progressive condition worsened and accelerated by each mood episode, which might resemble multiple sclerosis or rheumatoid arthritis as a condition that requires disease-modifying treatments to change illness trajectory. In this Personal View, we argue that lithium acts like a disease-modifying drug in bipolar disorder. Although the pathophysiology of bipolar disorder remains unclear, many of the mechanisms implicated in bipolar disorder, and the surrogate markers associated with this condition, are uniquely affected by lithium treatment from the DNA and cellular levels to the structure and function of the brain and other body systems. Clinical trial and cohort study evidence shows that lithium is effective and probably superior to other medications used to treat bipolar disorder, and that long-term outcomes are better with lithium than non-lithium regimens. Conceptualisation of lithium as a disease-modifying agent might help to increase clinical use by doctors, especially early in the disease course to better serve our patients.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Post RM, Li VW, Berk M, et al. Lithium as a disease-modifying drug for bipolar disorder. Lancet Psychiatry. 2025. PMID: 40505671. doi:10.1016/S2215-0366(25)00097-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。